We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s hold on approving Croatian drugmaker Pliva’s drug applications imposed after the agency cited it for current good manufacturing practice (cGMP) violations has been lifted, the company said.